Figure 2From: A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)Proportion of subjects with HIV-1 RNA <50 and <400 copies/mL through Week 48. Proportion of patients with HIV-1 RNA < 50 copies/mL (solid line) and < 400 copies/mL (dashed line): ITT(E), M/S = F analysis.Back to article page